Diabetes and pancreatic cancer

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 4, 2012, Pages 331-345

  Muniraj, T ^a   Chari, S T ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Diabetes mellitus; Glucose intolerance; Hyperinsulinemia; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CARBOHYDRATE; GLYCOPROTEIN; INSULIN GLARGINE; METFORMIN;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; EPIDEMIOLOGICAL DATA; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PATHOGENESIS; PREVALENCE; REVIEW; SEROLOGY;

AGE FACTORS; BODY MASS INDEX; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; GLUCOSE INTOLERANCE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; META-ANALYSIS AS TOPIC; METFORMIN; OBESITY; PANCREATIC NEOPLASMS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 84873508239     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. (Pubitemid 38339364)
2. Pancreatic cancer statistics 1/13/2012 ed. cancer.org: American Cancer Society 2012.
3. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83. (Pubitemid 47321600)
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl 1):S64-71.
5. Noy A, Bilezikian JP. Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab 1994;79:1223-31.
6. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 2012;107:620-6.
7. . Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101-7. (Pubitemid 23112386)
8. Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion and action in patients with pancreatic cancer. Cancer 1991;67:486-93.
9. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
10. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981-7. (Pubitemid 351451984)
11. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008;134:95-101. (Pubitemid 350309328)
12. Aggarwal G, Rabe KG, Petersen GM, Chari ST. New-onset diabetes in pancreatic cancer: A study in the primary care setting. Pancreatology 2012;12:156-61.
13. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9.
14. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 1996;13:337-40. (Pubitemid 26141699)
15. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-9.
16. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83. (Pubitemid 40897433)
17. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011;47:1928-37.
18. Lyons TJ. Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes. Semin Vasc Med 2002;2:175-89.
19. Salpea KD, Humphries SE. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010;209:35-8.
20. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010;170:791-802.
21. Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 2011;129:1708-17.
22. Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer RM, Park Y, Freedman DM et al. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control 2010;21:1305-14.
23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
24. Chari ST, Zapiach M, Yadav D, Rizza RA. Beta-cell function and insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology 2005;5:229-33. (Pubitemid 40754742)
25. Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872-8. (Pubitemid 41785868)
26. Prizment AE, Gross M, Rasmussen-Torvik L, Peacock JM, Anderson KE. Genes related to diabetes may be associated with pancreatic cancer in a population-based case-control study in Minnesota. Pancreas 2012;41:50-3.
27. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
28. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:e33411.
29. Azar M, Lyons TJ. Diabetes, insulin treatment, and cancer risk: what is the evidence? F1000 Med Rep 2010;2.
30. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008;114:38-44. (Pubitemid 351998750)
31. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-9.
32. Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 2008;40:369-74. (Pubitemid 351967126)
33. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007;39:65-7. (Pubitemid 46535160)
34. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44.
35. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-54.
36. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-65.
37. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
38. Rosenstock J, Fonseca V, McGill JB, Riddle M, Halle JP, Hramiak I et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971-3.
39. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-506.
40. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009;52:2507-12.
41. Gerstein H YS, Riddle MC, Ryden L, Bosch J. ORIGIN (Outcome Reduction with Initial Glargine Intervention). 2008 ed. Hamilton, Canada; 2008.
42. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32, e1-6.
43. Fogar P, Pasquali C, Basso D, Sperti C, Panozzo MP, Tessari G et al. Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 1994;14:2827-30.
44. Permert J, Larsson J, Ihse I, Pour PM. Diagnosis of pancreatic cancer. Alteration of glucose metabolism. Int J Pancreatol 1991;9:113-7.
45. Gullo L, Ancona D, Pezzilli R, Casadei R, Campione O. Glucose tolerance and insulin secretion in pancreatic cancer. Ital J Gastroenterol 1993;25:487-9. (Pubitemid 24022944)
46. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993;80:1047-50. (Pubitemid 23261595)
47. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007;102:2157-63. (Pubitemid 47493852)
48. Permert J, Larsson J, Westermark GT, Herrington MK, Christmanson L, Pour PM, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 1994;330:313-8. (Pubitemid 24041375)
49. Basso D, Brigato L, Veronesi A, Panozzo MP, Amadori A, Plebani M. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res 1995;15:2585-8. (Pubitemid 26095065)
50. Basso D, Valerio A, Brigato L, Panozzo MP, Miola M, Lucca T et al. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas 1997;15:132-8. (Pubitemid 27524688)
51. Wang F, Larsson J, Abdiu A, Gasslander T, Westermark P, Adrian TE et al. Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int J Pancreatol 1997;21:157-64. (Pubitemid 27278614)
52. Isaksson B, Strommer L, Friess H, Buchler MW, Herrington MK, Wang F et al. Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas 2003;26:173-7. (Pubitemid 36278305)
53. CDC National Diabetes Fact Sheet. January 10, 2012 ed. Center for Disease Control Center for Disease Control 2011.
54. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev 2012;28:338-42.
55. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg 2001;25:452-60. (Pubitemid 32455198)
56. Damiano J, Bordier L, Le Berre JP, Margery J, Dupuy O, Mayaudon H et al. Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab 2004;30:203-7. (Pubitemid 38715180)
57. Ogawa Y, Tanaka M, Inoue K, Yamaguchi K, Chijiiwa K, Mizumoto K et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 2002;94:2344-9. (Pubitemid 34457114)
58. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-11. (Pubitemid 41096638)
59. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol 2007;34:284-94. (Pubitemid 47176620)
60. Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas 2011;40:768-72.
61. Permert J, Larsson J, Fruin AB, Tatemoto K, Herrington MK, von Schenck H et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas 1997;15:60-8. (Pubitemid 27527361)
62. Permert J, Herrington M, Kazakoff K, Pour PM, Adrian TE. Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog Carcinog Mutagen 2001;21:59-67.
63. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 2001;121:640-5. (Pubitemid 32822579)
64. Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol 1999;34:833-44.
65. Rhodes JM, Ching CK. Serum diagnostic tests for pancreatic cancer. Baillieres Clin Gastroenterol 1990;4:833-52.
66. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
67. Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E et al. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma. Surg Oncol 1996;5:49-63. (Pubitemid 26242568)
68. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007;33:266-70. (Pubitemid 46488663)
69. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5. (Pubitemid 20140602)
70. Ringel J, Lohr M. The MUC gene family: their role in diagnosis and early detection of pancreatic cancer. Mol Cancer 2003;2:9.
71. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol 1982;2:135-40. (Pubitemid 13227806)
72. Podolsky DK. Serologic markers in the diagnosis and management of pancreatic carcinoma. World J Surg 1984;8:822-30. (Pubitemid 15024903)
73. Basso D, Fabris C, Panucci A, Del Favero G, Angonese C, Plebani M et al. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis. Int J Pancreatol 1988;3(Suppl 1):S95-100.
74. Kiriyama S, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Ono H et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 1990;65:1557-61. (Pubitemid 20106115)
75. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res 1988;48:1435-8. (Pubitemid 18091183)
76. Frena A. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker. Int J Biol Markers 2001;16:189-97. (Pubitemid 33039925)
77. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994;120:494-7. (Pubitemid 24205127)
78. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999;19:849-51. (Pubitemid 29168343)
79. Uemura M, Winant RC, Brandt AE. Immunoassay of serum galactosyltransferase isoenzyme II in cancer patients and control subjects. Cancer Res 1988;48:5335-41.
80. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007;34:436-43. (Pubitemid 46725785)
81. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-6. (Pubitemid 43166133)
82. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009;6:e1000046.
83. Satake K, Chung YS, Umeyama K, Takeuchi T, Kim YS. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study. Cancer 1991;68:149-52.
84. Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 2004;182:897-903. (Pubitemid 38391649)
85. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007;95:142-7. (Pubitemid 46238983)
86. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer 1986;54:897-901. (Pubitemid 17204439)
87. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005;31:164-9. (Pubitemid 40214752)
88. Zhao XY, Yu SY, Da SP, Bai L, Guo XZ, Dai XJ et al. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 1998;4:147-9. (Pubitemid 128620133)
89. Chung YS, Ho JJ, Kim YS, Tanaka H, Nakata B, Hiura A et al. The detection of human pancreatic cancer-associated antigen in the serum of cancer patients. Cancer 1987;60:1636-43. (Pubitemid 17141020)
90. Kobayashi T, Kawa S, Tokoo M, Oguchi H, Kiyosawa K, Furuta S et al. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer. Scand J Gastroenterol 1991;26:787-97.
91. Sawabu N, Toya D, Takemori Y, Hattori N, Fukui M. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers. Int J Cancer 1986;37:693-6. (Pubitemid 16042061)
92. Kawa S, Oguchi H, Kobayashi T, Tokoo M, Furuta S, Kanai M et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991;64:899-902.